HA001 - Hatton
Área: 2 - Biologia pulpar

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Chronic systemic pain genes may have a role in the development of Apical Periodontitis
Francio J, Neves GST, Letra A, Carneiro E
Endodontia - PONTIFÍCIA UNIVERSIDADE CATÓLICA DO PARANÁ
Conflito de interesse: Não há conflito de interesse

Chronic pain (CP) has affected 30% of people worldwide. Apical periodontitis (AP) is a chronic inflammatory disease characterized by inflammation and destruction of periradicular tissues that result from an infected root canal system. Pain is often seen as a clinical manifestation of AP for which the pathogenesis and molecular players overlap with other CP conditions. For the selection of candidate genes, PubMed was searched using specific terms. 173 genes from studies investigating different chronic conditions were selected. Publications were screened by title and abstract; in cases where this presented insufficient information, the text of the publication was read. 16 genes were finally selected (BDNF, CAMK4, COMT, CTSG, CRHBP, HTR2A, IFRD1, IL1A, KCNS1, MMP9, RAMP1, SCN9A, SCN11A, TIMP1, TFNA, TRPV1). AP tissue samples (n=42) were collected immediately upon apical endodontic surgery. RNA extraction was performed using Trizol and cDNA was synthesized. Control tissues comprised healthy periodontal ligament tissue samples. mRNA levels of target genes were evaluated using SYBR green chemistry in using RT-qPCR and normalized to GAPDH. Data analysis was performed using the 2^−ΔΔCt method. P-values ≤ 0.05 were considered statistically significant.
CAMK4, COMT, MMP9, TIMP1 and TNFA were significantly up-regulated in AP tissues. Our findings suggest that these genes may have an important role in the chronic pain associated with Apical Periodontitis. Identifying genes expressed in AP improves knowledge of the condition and provide insight into new therapies.

---

HA002 - Hatton
Área: 2 - Terapia endodôntica

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Development and validation of a self-report instrument for the screening of apical periodontitis
Franciscatto GJ, Réquia EC, Rossi-Fedele G, Gauer G, Gomes MS
PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
Conflito de interesse: Não há conflito de interesse

This study aimed to develop and validate a self-report instrument to identify patients with apical periodontitis (SRAP). The content and face validities of a 45-item self-report questionnaire were evaluated and the construct validity was tested in a population of 179 individuals through Factor Analysis for Mixed Data (FAMD) and reliability tests (analysis of internal consistency and test-retest). For accuracy evaluation, the SRAP was completely answered by 182 individuals. Diagnostic findings of apical periodontitis (AP) were obtained from panoramic radiographs analysis. The area under the receiver operator curve (AUROC), accuracy, sensitivity (SS), specificity (SP), positive (PPV) and negative predictive values (NPV), positive (PLR) and negative likelihood ratios (NLR) were calculated. After face and content validation, 38 items remained in the pool. After FAMD, 8 items were retained with a Cronbach's alpha of 0.85. The model included 3 factors that explained 33.05% of variance in data: history of endodontic treatment, oral health self-evaluation and history of oral trauma. The prevalence of AP was 54.3%. The SRAP values for the diagnosis of AP were: AUROC (0.685), accuracy (0.615); SS (0.636); SP (0.590); PPV (0.649); NPV (0.576); PLR (1.207) and NLR (0.615).
The 8-item SRAP presented good indexes of construct validity and reliability, showing a predictive power for AP in up to 65% of cases. The SRAP is a low cost, fast and easy to apply instrument, representing an encouraging tool to be used in large-scale population screenings and public health scenarios.
(Apoio: CAPES  N° 001  |  Australian Academy of Sciences  N° 2018)

---

HA003 - Hatton
Área: 3 - Controle de infecção / Microbiologia / Imunologia

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Effects of nano-sized sodium hexametaphosphate and fluoride on dual-species biofilms of Streptococcus mutans and Candida albicans
Sampaio C, Delbem ACB, Fernandes AVP, Hosida TY, Morais LA, Camargo ER, Monteiro DR, Pessan JP
Odontologia Preventiva e Restauradora - UNIVERSIDADE ESTADUAL PAULISTA - ARAÇATUBA
Conflito de interesse: Não há conflito de interesse

This study evaluated the effects of nano-sized sodium hexametaphosphate (HMPnano), combined or not with fluoride (F), on dual-species biofilms of Streptococcus mutans and Candida albicans. Solutions containing micrometric HMP (HMPmicro) or HMPnano were prepared at 0.5 or 1%, combined or not with 1,100 ppm F; 1,100 ppm F and artificial saliva were tested as positive and negative controls, respectively. Dual-species biofilms of S. mutans and C. albicans, grown in microtiter plates, were treated (1 min) with the solutions at 72, 78 and 96 h from the beginning of their formation. Biofilms were analyzed by colony-forming unit counting (CFU), metabolic activity (XTT assay), and production of total biomass (crystal violet assay). Data were submitted to ANOVA or Kruskal Wallis test, followed by Tukey's or Student-Newman-Keuls' tests (p<0.05). HMPnano at 1% + F led to the highest CFU reduction of S. mutans, followed by HMP micro at 1% + F and positive control (similar to each other), and the remaining groups; CFU counts of C. albicans were not affected by any solution assessed. Furthermore, HMPnano at 1% led to significant lower metabolic activity compared to all other groups (except for HMPnano at 1% + F). Also, all test solutions promoted significant reductions in biofilm biomass compared to both positive and negative controls.
It can be concluded that HMPnano promoted higher antibiofilm effects compared with its micrometric counterpart for most of the variables assessed, besides having a synergist action with F on CFU reduction of S. mutans.
(Apoio: CAPES  N° 001  |  CAPES  N° 88881.068437/2014-01  |  CNPq  N° 123611/2019-9)

---

HA004 - Hatton
Área: 3 - Controle de infecção / Microbiologia / Imunologia

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Adrenergic signaling and periodontitis: insights on innate immunity response and P. gingivalis virulence factors in an invertebrate model
Moraes RM, Stossi F, Garcia MT, Barros PP, Ribeiro JL, Anbinder AL
Biociências e Diagnóstico Bucal - INSTITUTO DE CIÊNCIA E TECNOLOGIA / ICT-UNESP-SJC
Conflito de interesse: Não há conflito de interesse

Stress is a risk factor for periodontitis, however, the interrelationship between stress (adrenergic system), innate immune response and virulence of periodontopathogens (e.g., Porphyromonas gingivalis-Pg) is still unclear. The study of stress in humans involves variables that are difficult to control, besides individual variations, the complexity of immune response and microbiota. Invertebrate models are a good alternative, as they have similar innate immune response and enable controlled infections. We investigated the action of adrenergic signaling by comparing norepinephrine-NE (α and β agonist) and isoproterenol-ISO (β agonist) on Galleria mellonella immune response and Pg virulence. Dose and time-responses on toxicity and hemocyte density were measured. Both ligands showed opposite effects 30 minutes post-injection: ISO increased the hemocyte number by stimulating sessile hemocyte detachment from the fat body, and NE decreased it. This phenotype correlated with a protective effect of ISO on larval mortality after Pg injection, while NE enhanced the death rate. ISO and NE had similar effects on melanization. Pg was also cultivated in the presence of ISO or NE and then injected into the larvae, to evaluate the direct effects of the ligands on bacterial virulence. ISO-grown bacteria increased the death rate compared to standard Pg controls, and NE had no significant effect.
There is a complex interrelation among stress receptors, innate immune response and bacterial virulence, and their balance is what determines the infection's ultimate outcome.
(Apoio: FAPs - FAPESP  N° 2018/25933-3  |  FAPs - FAPESP  N° 2017/26461-5  |  FAPs - FAPESP  N° 2018/21701-0)

---

HA005 - Hatton
Área: 3 - Fisiologia / Bioquimica / Farmacologia

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Metabolomic identification of novel salivary biomarkers for diagnostic and monitoring Diabetes
Moura DV, Caixeta DC, Santos P, Martins MM, Goulart LR, Sabino-Silva R
Fisiologia - UNIVERSIDADE FEDERAL DE UBERLÂNDIA
Conflito de interesse: Não há conflito de interesse

The diagnostic and monitoring of glycemia is an invasive and painful in diabetes mellitus (DM).Consequently, the search for non-invasive diagnostic biomarkers is of great interest in DM. The limitation to use saliva in clinical settings can be related to the reduced chemical composition knowledge. Here, a characterization of the salivary metabolome is presented in a diabetic animal model. Fluid chromatography coupled to mass spectrometry with time-of-flight system were employed to spot the metabolites in rats saliva. Fifteen Wistar rats were divided in non-diabetic (ND), diabetic (D) and diabetic 6U-treated of insulin (D6U). DM was induced by an intraperitoneal injection (60 mg/kg) of streptozotocin (STZ). The animals were submitted to 28 days of diabetes, and on the 21st day, the insulin- or placebo-treatment was started (#CEUA 13/16). The glycemia and urinary glucose confirmed the diabetic state. The metabolic salivary profile identified hundreds of novel compounds with potential to discriminate diabetes. Principal Component Analysis and clustering indicates 3 main candidates as novel salivary metabolites for salivary screening of diabetes: N-Arachidonoyl tyrosine, 1-11-Eicosenoyl-Triacylglycerol and Dimethylphosphatidylethanolamine (22:5(7Z/24:1(15Z) HMDB, (ANOVA).
Altogether, this salivary metabolomic analysis indicates novel salivary metabolites candidates to be applied in salivary diagnostic salivary platforms for non-invasive diabetic diagnostic platforms and for the salivary monitoring tool during insulin treatment.
(Apoio: CAPES  N° (#23038.014934/2020-59).  |  FAPEMIG  N° (#APQ-02872-16)  |  INCT-TeraNano  N° (465669/2014-0))

---